NDA 019787 · Viatris
Norvasc
Amlodipine Besylate · Oral
NovelLast checked: Nov 19, 2026Latest source record: Oct 30, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1992
Jul 31, 1992
Approved uses
5
Original approval plus efficacy supplements
Registered trials
656
178 Phase 3, 22 recruiting
FAERS reports
147,838
101,630 serious, 13,282 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 28, 2024.
Amlodipine besylate is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension ( 1.1 ) o Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease ( 1.2 ) o Chronic Stable Angina o Vasospastic Angina (Prinzmetal’s or Variant Angina) o Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40% 1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce...
Mechanism: Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 28, 2005 Supplement 38 · Efficacy LetterLabel
- Jan 8, 2004 Supplement 30 · Efficacy ReviewLetter
- Jul 12, 2000 Supplement 20 · Efficacy ReviewLetter
- Jun 14, 1996 Supplement 7 · Efficacy Review
- Jul 31, 1992 Original approval · Type 1 - New Molecular Entity
3 products under this application
- NORVASC · AMLODIPINE BESYLATE EQ 5MG BASE · TABLET, ORAL · Prescription · TE AB
- NORVASC · AMLODIPINE BESYLATE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
- NORVASC · AMLODIPINE BESYLATE EQ 2.5MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Amlodipine" as an intervention, any sponsor and status, largest first.
- China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)Pivotal-lookingRecruiting
Shenzhen Ausa Pharmed Co.,LtdIndustry
NCT04974138 · 32,000 participants (planned) · Start Aug 22, 2024 · Primary completion Jun 30, 2030
Drug: Amlodipine besylate; Amlodipine besylate and folic acid and 2 more · For: Hypertension; MTHFR 677 CC or CT Genotype; Elevated Plasma Homocysteine (Hcy≥10µmol/L) and 1 more
Sites: Bengbu, China; Bozhou, China; Chizhou, China · 20 sites in all
- China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT GenotypePivotal-lookingRecruiting
Shenzhen Ausa Pharmed Co.,LtdIndustry
NCT04974151 · 24,000 participants (planned) · Start Aug 22, 2024 · Primary completion Jun 30, 2029
Drug: Amlodipine besylate; Amlodipine besylate And Folic Acid and 4 more · For: Hypertension; MTHFR 677 TT Genotype
Sites: Bengbu, China; Bozhou, China; Chizhou, China · 20 sites in all
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00741585 · 21,983 participants · Start Sep 1, 2008 · Primary completion Jun 30, 2018
Drug: Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination · For: Essential Hypertension; Cardiovascular Disease; Stroke and 1 more
Sites: Friol, Spain; A Estrada, Spain; Baiona, Spain · 20 sites in all
- Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential HypertensionPivotal-lookingCompleted
Oslo University HospitalAcademic, hospital or other
NCT06395194 · 15,313 participants · Start Sep 27, 1997 · Primary completion Sep 5, 2003
Drug: Cardiac outcomes on treatment with valsartan; Cardiac outcomes on treatment with amlodipine · For: Essential Hypertension
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
- Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVDPivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT05169021 · 15,000 participants (planned) · Start Dec 31, 2021 · Primary completion Dec 31, 2024
Drug: Amlodipine folic acid 5.8mg+intensive antihypertensive therapy; Amlodipine folic acid 5.8mg+standard antihypertensive therapy and 2 more · For: Cerebral Small Vessel Diseases; Stroke
Sites: Beijing, China
- Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive PatientsPivotal-lookingStatus unknown
Chinese Academy of Medical Sciences, Fuwai HospitalAcademic, hospital or other
NCT01011660 · 13,542 participants (planned) · Start Oct 2007 · Primary completion Aug 2012
Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin · For: Essential Hypertension
Sites: Beijing, China
- Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic HypertensionPivotal-lookingTerminated
NovartisNovartis (NVS)
NCT00170950 · 11,506 participants · Start Oct 2003 · Primary completion Jan 2008
Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1; Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 and 4 more · For: Hypertension
Sites: East Hanover, New Jersey; Denmark, Denmark; Finland, Finland · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue9,860
- nausea8,456
- diarrhoea8,041
- dyspnoea8,012
- drug ineffective7,201
- pain6,914
- dizziness6,652
- headache6,590
- asthenia5,824
- pneumonia5,482
- fall5,476
- off label use5,428
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3,379 |
| 2005 | 3,869 |
| 2006 | 4,019 |
| 2007 | 3,206 |
| 2008 | 3,180 |
| 2009 | 3,982 |
| 2010 | 5,808 |
| 2011 | 6,230 |
| 2012 | 6,673 |
| 2013 | 4,898 |
| 2014 | 6,580 |
| 2015 | 7,687 |
| 2016 | 8,465 |
| 2017 | 7,500 |
| 2018 | 7,955 |
| 2019 | 7,850 |
| 2020 | 7,320 |
| 2021 | 7,565 |
| 2022 | 9,886 |
| 2023 | 8,342 |
| 2024 | 8,301 |
| 2025 | 8,803 |
| 2026 | 6,327 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Norvasc (Amlodipine Besylate)
2024 spending
$14.5M
Beneficiaries
5,263
20,746 claims
Per beneficiary
$2,747
$9.20 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $23,712,300 |
| 2021 | $18,209,247 |
| 2022 | $17,072,136 |
| 2023 | $16,337,514 |
| 2024 | $14,459,169 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
Xie M, Tang T, Liang H · Clin Cardiol 2023 · Systematic Review, Network Meta-Analysis
- Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis.
Yin J, Mei Z, Shi S, et al. · Arch Gynecol Obstet 2022 · Meta-Analysis, Systematic Review
- Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.
Jin X, Kim MH, Han KH, et al. · J Clin Hypertens (Greenwich) 2020 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Amlodipine reduces blood pressure during dynamic resistance exercise in hypertensive patients.
Souza DR, Gomides RS, Costa LA, et al. · Scand J Med Sci Sports 2015 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients.
Kloner RA, Vetrovec GW, Materson BJ, et al. · Am J Cardiol 1998 · Comparative Study, Meta-Analysis
- A comparison of amlodipine with enalapril in the treatment of moderate/severe hypertension.
Fowler G, Webster J, Lyons D, et al. · Br J Clin Pharmacol 1993 · Clinical Trial, Comparative Study
Sponsor: Viatris
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.